|
|
|
|
CerezymeMSN Money Fourth-quarter sales of Cerezyme(R) (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $232 million, 6 percent greater ... Genzyme's Revenue Set to Climb Jan 9, 2006 TheStreet.com Analysts surveyed by Thomson First Call were expecting revenue of $729.9 million. Sales of one of its top drugs, Cerezyme, climbed 6% to $232 million. ... Genzyme 4th-qtr revenue rises 22 pct on drug sales Jan 9, 2006 Reuters Sales of Cerezyme, the company's treatment for Gaucher disease, a condition that causes enlargement of the liver and spleen, rose 6 percent to $232 million. ... Early numbers from Genzyme show 24% revenue rise Jan 9, 2006 Boston Business Journal, Its drug Cerezyme, designed to treat the enzyme disorder Gaucher disease, jumped to $933 million in sales in fiscal 2005, up from $839 million the year before. ... BioMarin Establishes Commercial Operations in Europe Jan 10, 2006 PR Newswire (press release), ...responsible for overseeing the development and implementation of reimbursement planning and launch for multiple products, including Cerezyme and Ceredase. ... As biotech drug prices rise, US hunts for solution Dec 28, 2005 Pittsburgh Post Gazette, For example, Genzyme Corp.'s Gaucher Disease drug, Cerezyme, is priced at $200,000 for the average patient today, 14 years after the first version came to ... Medicare Rx Rolls Out Jan 3, 2006 Bangor Daily News, ...expensive special drugs. For example, Cerezyme, a specific for Gaucher's disease, costs as much as $200,000 a year. Plan D would ... Montgomery & Co., LLC Announces Investment Opinion: Initiates ... Dec 19, 2005 Business Wire (press release), Genzyme's key products include Cerezyme for Gaucher's disease, Renagel for chronic kidney disease and Fabrazyme for Fabry's disease. Montgomery & Co. ... |
|
Home Copyright phasechange.org 2006. All Rights Reserved. |